Streetbeat News

Stock Prices

RCMT

RCM Technologies (NASDAQ:RCMT) reported Q4 earnings with an EPS of $0.71, beating estimates by 15.0% against an expected $0.62. Revenue increased by $807 thousand from the previous year. The company has a history of surpassing EPS estimates, which in the past has led to a significant share price increase the following day.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 8:15 pm

QNRX

Quoin Pharmaceuticals (NASDAQ:QNRX) reported Q4 earnings, beating estimated EPS by 10.0% with an EPS of $-2.08 versus an estimate of $-2.31. However, revenue was unchanged from the same period last year. In the previous quarter, beating EPS estimates was followed by an 8.0% drop in share price the next day.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 8:15 pm

PATH

UiPath has projected its FY25 revenue to be between $1.555 billion and $1.560 billion, surpassing the estimated $1.531 billion.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 8:14 pm

PATH

UiPath projects its Q1 2025 revenue to be between $330M and $335M, which is below the estimated $347.851M.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 8:14 pm

VRM

Vroom's stock price declined following the announcement of its Q4 financial results.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 8:14 pm

PATH

UiPath (NYSE:PATH) reported Q4 2024 adjusted EPS of $0.22, surpassing the $0.16 estimate, with sales of $405.253M exceeding the $383.826M forecast. This represents a 31.34% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 8:12 pm

SPRO

Spero Therapeutics (NASDAQ:SPRO) reported Q4 2023 earnings of $0.96 per share, surpassing the $(0.10) estimate by 1060%, and a 74.55% increase from last year's $0.55. Sales reached $73.524M, beating the $18.633M estimate by 294.58%, and marking a 54.98% increase from the previous year's $47.441M.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 8:12 pm

TXG

10x Genomics, Inc. (NASDAQ:TXG) has started commercial shipments of its next-generation single cell technology products, Chromium Single Cell Gene Expression 3' v4 and Chromium Single Cell Immune Profiling 5' v3, powered by the new GEM-X technology. GEM-X offers enhanced performance, including up to two times more gene detection, a two-fold increase in cells captured per channel, more than two-fold reduction in cost per cell, and improved data quality. These advancements are expected to significantly benefit research in single cell and spatial biology.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 8:11 pm

SCPH

scPharmaceuticals (NASDAQ:SCPH) reported Q4 earnings with an EPS of $-0.35, beating estimates by 17.0% and showing a revenue increase of $6.10 million from the previous year. However, the company had missed EPS estimates in the last quarter, leading to a 9.0% share price drop the following day.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 8:10 pm

KRMD

KORU Medical Systems (NASDAQ:KRMD) reported Q4 earnings, beating estimates with an EPS of $-0.02 against an expected $-0.04 but saw a revenue decrease of $159k from the previous year. Despite beating EPS estimates, past performance shows a share price drop following earnings beats.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 8:10 pm